Compare with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PFIZER ALKEM LABORATORIES/
PFIZER
 
P/E (TTM) x 24.6 43.4 56.7% View Chart
P/BV x 5.9 7.2 82.8% View Chart
Dividend Yield % 0.8 0.5 171.5%  

Financials

 ALKEM LABORATORIES   PFIZER
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
PFIZER
Mar-19
ALKEM LABORATORIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs2,7203,840 70.8%   
Low Rs1,6602,080 79.8%   
Sales per share (Unadj.) Rs697.9455.0 153.4%  
Earnings per share (Unadj.) Rs96.193.8 102.5%  
Cash flow per share (Unadj.) Rs117.3109.4 107.2%  
Dividends per share (Unadj.) Rs25.0022.50 111.1%  
Dividend yield (eoy) %1.10.8 150.2%  
Book value per share (Unadj.) Rs515.2658.2 78.3%  
Shares outstanding (eoy) m119.5745.75 261.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.16.5 48.2%   
Avg P/E ratio x22.831.6 72.2%  
P/CF ratio (eoy) x18.727.1 69.0%  
Price / Book Value ratio x4.34.5 94.5%  
Dividend payout %26.024.0 108.4%   
Avg Mkt Cap Rs m261,879135,420 193.4%   
No. of employees `00014.32.6 544.7%   
Total wages/salary Rs m15,0553,238 464.9%   
Avg. sales/employee Rs Th5,822.67,911.4 73.6%   
Avg. wages/employee Rs Th1,050.51,230.9 85.3%   
Avg. net profit/employee Rs Th802.01,630.7 49.2%   
INCOME DATA
Net Sales Rs m83,44420,815 400.9%  
Other income Rs m1,0421,674 62.3%   
Total revenues Rs m84,48622,489 375.7%   
Gross profit Rs m14,7345,712 257.9%  
Depreciation Rs m2,528714 354.1%   
Interest Rs m65173 892.5%   
Profit before tax Rs m12,5986,599 190.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1052,309 47.9%   
Profit after tax Rs m11,4934,291 267.9%  
Gross profit margin %17.727.4 64.3%  
Effective tax rate %8.835.0 25.1%   
Net profit margin %13.820.6 66.8%  
BALANCE SHEET DATA
Current assets Rs m54,96027,167 202.3%   
Current liabilities Rs m32,4338,917 363.7%   
Net working cap to sales %27.087.7 30.8%  
Current ratio x1.73.0 55.6%  
Inventory Days Days8068 117.3%  
Debtors Days Days7230 239.7%  
Net fixed assets Rs m32,7108,862 369.1%   
Share capital Rs m239458 52.3%   
"Free" reserves Rs m61,36829,656 206.9%   
Net worth Rs m61,60730,113 204.6%   
Long term debt Rs m1,59225 6,369.6%   
Total assets Rs m99,43339,400 252.4%  
Interest coverage x20.491.5 22.2%   
Debt to equity ratio x00 3,113.5%  
Sales to assets ratio x0.80.5 158.8%   
Return on assets %12.211.1 110.3%  
Return on equity %18.714.2 130.9%  
Return on capital %21.022.1 94.7%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,061428 3,750.0%   
Fx outflow Rs m2,483786 315.7%   
Net fx Rs m13,578-358 -3,791.8%   
CASH FLOW
From Operations Rs m5,851978 598.2%  
From Investments Rs m-7,414351 -2,110.9%  
From Financial Activity Rs m792-1,099 -72.1%  
Net Cashflow Rs m-731231 -316.8%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 33.1 7.5 441.3%  
FIIs % 0.0 4.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 23.7 -  
Shareholders   68,381 85,207 80.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ORCHID PHARMA  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Plunged 2% Today(Closing)

Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.

Related Views on News

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 27, 2021 03:36 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - GSK PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS